Skip to main content

Table 1 Power for the overall population, culture-negative patients and culture-positive patients based on the assumptions above

From: Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial

Total sample size in both groups (culture-positive/-negative) All patients (ITT): power for superiority of azithromycin Culture-negative patients: power for superiority of azithromycin Culture-positive patients: power for “non-inferiority” of azithromycina
300 (150/150) 80% 89% 96%
300 (100/200) 92% 95% 86%
  1. aProbability that the 95% confidence interval for the effect of azithromycin excludes the possibility that azithromycin is associated with a 1.5-fold slower fever clearance time (FCT) in culture-positive patients. ITT intention-to-treat